Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma.

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer.

A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women’s Hospital, is the corresponding author of a paper published in the Journal of Clinical Oncology, “Comparative Analysis ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...

Becomes the first subcutaneously administered PD-1 inhibitor.

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.